Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

ABSTRACT Objective: Vildagliptin is a potent and selective dipeptidyl peptidase‑IV (DPP‑4) inhibitor that improves glycemic control in patients with type 2 diabetes by increasing alpha and beta-cell responsiveness to glucose. This study assessed the effect of multiple doses of vildagliptin 100 mg on...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current medical research and opinion 2007-05, Vol.23 (5), p.1131-1138
Hauptverfasser:	He, Yan-Ling, Sabo, Ron, Riviere, Gilles-Jacques, Sunkara, Gangadhar, Leon, Selene, Ligueros-Saylan, Monica, Rosenberg, Mitchell, Dole, William P., Howard, Dan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adamantane - administration & dosage Adamantane - adverse effects Adamantane - analogs & derivatives Adamantane - blood Adamantane - pharmacokinetics Administration, Oral Adult Anticoagulants - adverse effects Anticoagulants - blood Anticoagulants - pharmacokinetics Cross-Over Studies Dipeptidyl-Peptidase IV Inhibitors Drug Administration Schedule Drug interaction Drug Interactions Female Health Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - blood Hypoglycemic Agents - pharmacokinetics International normalized ratio Male Nitriles - administration & dosage Nitriles - adverse effects Nitriles - blood Nitriles - pharmacokinetics Pharmacokinetics Prothrombin time Pyrrolidines - administration & dosage Pyrrolidines - adverse effects Pyrrolidines - blood Pyrrolidines - pharmacokinetics Vildagliptin Warfarin Warfarin - administration & dosage Warfarin - adverse effects Warfarin - blood Warfarin - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!